Can You Get GLP-1 Medications Without Meeting BMI Requirements?

The BMI Problem in Weight Loss Medicine

Body Mass Index was invented in the 1830s as a statistical tool for population comparisons. In 2026, it remains the primary gating criterion for most weight loss medication prescriptions — a situation that frustrates patients and physicians alike. A person who is 5'8" and weighs 175 lbs has a BMI of 26.6 — technically "overweight" but below the 27 threshold required for GLP-1 eligibility with a comorbidity, and far below 30.

Yet that same person may have significant visceral adiposity, elevated fasting insulin, prediabetes, or metabolic syndrome — all markers that indicate elevated cardiometabolic risk and that GLP-1 medications could meaningfully address. BMI tells you nothing about where fat is stored, muscle mass, or metabolic function.

This guide explores the official eligibility thresholds, the conditions that can qualify patients at lower BMIs, and how forward-thinking providers approach eligibility beyond the simple BMI number. For a broader overview of starting GLP-1 treatment, see our complete guide to starting semaglutide.

Official FDA Eligibility Thresholds

These are FDA labeling criteria — the thresholds under which pharmaceutical companies ran their pivotal clinical trials. They do not prevent physicians from prescribing outside these thresholds (off-label use is legal), but they do determine insurance coverage and the standard of care most providers follow.

Conditions That May Qualify You at BMI 27–29

If your BMI is between 27 and 30 and you have any of the following conditions, you likely meet standard eligibility criteria:

Beyond BMI: What Modern Providers Evaluate

Leading obesity medicine specialists and forward-thinking telehealth providers are increasingly moving beyond BMI as the sole criterion. The factors they consider include:

• Waist circumference: Abdominal obesity (waist >35" for women, >40" for men) indicates visceral adiposity regardless of BMI
• Fasting insulin and HOMA-IR: Insulin resistance is a key driver of metabolic disease even at normal BMI
• HbA1c and fasting glucose: Prediabetes range (5.7–6.4%) indicates significant future risk
• Triglyceride/HDL ratio: A proxy for insulin resistance and cardiovascular risk
• PCOS: GLP-1 medications improve insulin sensitivity and hormonal profiles in PCOS, even at lower BMIs. See our complete PCOS guide
• NAFLD/NASH: Non-alcoholic fatty liver disease responds strongly to GLP-1 treatment regardless of BMI. See our article on semaglutide for fatty liver
• Mental health and quality of life: Some providers factor in the psychological burden of weight-related concerns

Ethnic-Specific BMI Thresholds

Asian and South Asian populations have been shown to develop obesity-related metabolic complications at lower BMI values than populations used to establish the standard 30/27 thresholds. Many clinical guidelines recommend lower action thresholds for these groups:

Providers treating patients from these populations should (and increasingly do) apply adjusted thresholds when evaluating GLP-1 candidacy.

How to Talk to Your Provider About Eligibility

If you believe you would benefit from GLP-1 treatment but are concerned about not meeting standard BMI criteria, the most productive approach is to frame the conversation around your metabolic health rather than weight alone. Come prepared with lab work (fasting glucose, HbA1c, lipid panel, fasting insulin if available), a description of your weight-related health concerns, and any family history of diabetes or cardiovascular disease.

Trimi's medical assessment process evaluates each patient individually, looking at the full clinical picture rather than applying a rigid BMI cutoff. Learn what Trimi's assessment involves, or get started directly at our how it works page.